Hallucinations during lamotrigine treatment

Nurse Practitioner

Volumn 33, Issue 3, 2008, Pages 12-13

  Roberts, Christina K ^a   Davenport, Robin ^a   Patel, Harsha N ^a   Patel, Nitin C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; LAMOTRIGINE; TRIAZINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADOLESCENT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; ERYTHEMA INFECTIOSUM; FEMALE; HALLUCINATION; HUMAN;

ADOLESCENT; AMITRIPTYLINE; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ERYTHEMA INFECTIOSUM; FEMALE; HALLUCINATIONS; HUMANS; TRIAZINES; VALPROIC ACID;

EID: 44449123722     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000312994.16081.39     Document Type: Article

References (5)

1. Panayiotopoulos C. A Clinical Guide to Epileptic Syndromes and Their Treatment. Oxfordshire: Bladon Medical Publishing; 2002.
2. Faught E, Morris G, Jacobson M, et al. Adding lamotrigine to valproate: Incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia. 1999;40 (8):1135-1140.
3. Glauser TA. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neuro. 2004;19 (Suppl. 1):S25-S38.
4. Ropper A, Brown R. Adams and Victor’s Principles of Neurology. 8th Edition. McGraw-Hill, Medical Publishing Division. 2005.
5. Prescribing Information for Lamictal Tablets and Lamictal Chewable Dispersible Tablets. GlaxoSmithKline Research Triangle Park, NC 27709. January 2003. Available at: http://us.gsk.com/products/assets/us_lamictal.pdf. Accessed January 23, 2008.